Treatments

*December 2020* EGFR, ALK, and ROS1 abnormalities are no longer the only oncogenic drivers worthy of discussion in non–small cell lung cancer (NSCLC), explained Stephen Liu, MD, who added that the field has seen an abundance of highly selective RET, MET, HER2, and KRAS inhibitors that have the potential to deliver durable responses.…

*December 2020* Robust data on the outcome of MET-aberrant non-small cell lung cancer (NSCLC) with non-targeted therapies is limited, especially in consideration of the heterogeneity of MET-amplified tumors. METex14, METamp GCN≥10, and METamp GCN<10 represent subgroups of MET-dysregulated NSCLC with distinct molecular and clinical features. METex14 patients do not seem to benefit from immunotherapy in contrast…

*December 2020* Identification of key oncogenic drivers and the development of targeted therapies with clinical activity in patients harboring actionable mutations have revolutionized the treatment paradigm in non–small cell lung cancer (NSCLC), redirecting attention toward advances in biomarker testing methodologies. This new focus is poised to foster granular refinement of…

*November 2020* Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, efficiently penetrates the blood-brain barrier. This study explored whether treatment with osimertinib leads to improved overall survival (OS) for patients with EGFR-mutated NSCLC with leptomeningeal metastases (LM) compared with those not treated with osimertinib. For the 351 patients with LM included…

*December 2020* Because no standard approaches exist for patients with EGFR-mutated non–small cell lung cancer (NSCLC) who progress on standard frontline osimertinib (Tagrisso), repeat genomic testing should be done to identify potential resistance mechanisms that can help guide the next step in the treatment journey, Rami Manochakian, MD. “This is a very…

*December 2020* John Heymach, MD, PhD Chair, Department of Thoracic/Head and Neck Medical Oncology The University of Texas MD Anderson Cancer Center in a Q&A session: Targeted Oncology™: How would you reassure a patient who is eager to start treatment? HEYMACH: Patients are anxious to get their treatment started. I…

*November 2020* This new clinical trial is for those people whose EGFR lung cancer has transformed to small cell lung cancer.This trial covers travel expenses as well. Any questions can be directed to Dr. Anish Thomas at: Anish.Thomas@nci.gov. (In addition to this trial, there are other NCI trials for small…

*November 2020* Neratinib (Nerlynx) showcased early activity when used in patients with metastatic non–small cell lung cancer (NSCLC) who harbor EGFR exon 18 mutations, according to interim data from the phase 2 SUMMIT trial.1 Results demonstrated that among 10 evaluable patients who received the EGFR inhibitor, 60% (n = 6) had a…

*November 2020* In the treatment of lung tumors, alterations in MET as well as gene fusions in RET and NTRK are now established actionable drivers of oncogenesis, made evident by the availability of FDA-approved and guidelines-indicated therapies for each other these aberrations. Alexander Drilon, MD, chief of Early Drug Development…